Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn’s disease

Table 6 Antiphospholipid antibodies, thrombophilia markers and clinical characteristics of total Crohn’s disease according to presence and type of thrombosis n (%)

Factor	Follow-up of CD Total Cohort from diagnosis (n = 265)
	No thrombosis	Arterial thrombosis	Venous thrombosis	No pregnancy loss	Pregnancy loss
	(n = 251)	(n = 3)	(n = 11)	(n = 146)	(n = 10)
Male/female	104/147	1/2	7/4	146/0	10/0
Age at presentation (yr)1	25.0 (19.0-33.0)	40.0 (28.0-42.0)	29.5 (23.3-39.3)	26.0 (20.0-35.0)	25.5 (21.0-35.0)
Frequent relapse	48 (20.2)	0 (0.0)	4 (36.4)	33 (24.1)	2 (20.0)
Previous thrombosis	1 (0.4)3	0 (0.0)	4 (36.4)3	2 (1.4)	0 (0.0)
Smoking habits yes	48 (19.1)	0 (0.0)	3 (27.3)	22 (15.1)	2 (20.0)
Follow up time from diagnosis, mo1	102.2 (63.3-172.8)2	149.9 (130.8-219.8)	186.3 (142.0-244.2)2	109.0 (61.8-184.6)	136.5 (95.4-180.6)
Positive markers (%)
Anti-β2-GPI IgG and/or IgM	4.8	0	9.1	4.9	10
Anti-β2-GPI IgA	2.8	0	0	4.9	0
ACA IgG and/or IgM	12.1	0	27.3	13.9	10
ACA IgA	19.0	66.7	0	20.1	10
Anti-PS/PT IgG and/or IgM	14.6	50.0	36.4	18.3	40
Anti-PS/PT IgA	8.9	50.0	9.1	7.7	10
At least 1 APLA pos	48.0	66.7	54.5	52.8	60
At least 2 APLA pos	16.1	33.3	9.1	18.1	10
At least 3 APLA pos	3.2	0	9.1	4.9	0
Thrombophilia markers3 (%)
LA	7.5	0	0	5.1	0
PS deficiency (inherited and/or acquired)	8.1	0	25.0	12.7	0
ATIII deficiency (inherited and/or acquired)	0	0	0	0	0
PC deficiency (inherited and/or acquired)	3.0	0	0	4.8	0
FV Leiden	5.94	0	42.94	7.8	0
FII20210A	5.9	0	16.7	7.8	0

¹Median (IQR);

²Using Kruskal-Wallis test (P≤ 0.01);

³Using χ²-test with Yates correction (P≤ 0.05);

⁴Serologic and genetic markers of thrombophilia were available in 105 patients. pts: Patients; APLA: Antiphospholipid antibodies; β2-GPI: Beta2-glycoprotein-I; ACA: Anti-cardiolipin antibody; PS/PT: Phosphatidylserine/prothrombin complex.